Table 2.
Atorvastatin Use in PCOS
| Author/Year | N (average age +/- SD)/ Study design/ Duration | Meds Used | Cholesterol Outcomes | Other Findings | Labs |
|---|---|---|---|---|---|
| Sathyapalan T, et al.21 (2009) | 40 PCOS women (atorvastatin group: 26.6 +/- 1.2; placebo group: 28.8 +/- 1.8), randomized double-blind placebo-controlled, 12 week study | Atorvastatin vs. placebo | -TC decreased by 26% vs. 2% -LDL decreased by 36% vs. no change -TG decreased by 21% vs. increased by 18% -No detectable changes in HDL |
-Total T decreased by 25% (p < 0.01) -Hs-CRP reduced by 25% (p = 0.05) -Insulin levels decreased by 21% (p < 0.01) |
TC, LDL, TG, hs-CRP, T levels |
| Sathyapalan T, et al.22 (2012) Extension Study of Sathyapalan T, et al.21 (2009) |
40 PCOS women (atorvastatin group: 26.6 +/- 1.2; placebo group: 28.8 +/- 1.8), randomized double-blind placebo-controlled, 3 month study | Atorvastatin vs. placebo followed by subsequent 12 weeks of metformin | Not studied | -DHEAS decreased by 15% (p = 0.02) -Androstenedione decreased by 17% (p = 0.03) -No significant changes in either androstenedione or -DHEAS concentrations in placebo group after 12 weeks of metformin |
DHEA, androstenedione |
| Raja-Khan N, et al.23 (2011) | 20 women with PCOS (atorvastatin group: 33.8 +/- 4.3; placebo: 29.4 +/- 5.8), double-blind randomized placebo-controlled trial, 6 week study | Atorvastatin 40 mg daily vs. placebo | -TC decreased by 39% vs. 5% -No significant Hchange in HDL -LDL decreased by 51% vs. 9% -TG decreased by 49% vs. increased by 5% |
-Androstenedione decreased by 26% vs. increased by 7% (p < 0.001) -DHEAS decreased by 18.6% vs. increased by 2% (p = 0.02) -Hs-CRP decreased by 46% (p = 0.02) vs. 16.7% -Insulin AUC worsened by 27% (p = 0.03) vs. improved by 2% (p = 0.79) |
TC, HDL, LDL, TG, hs-CRP, androstenedione, total T, DHEAS, glucose/insulin, FMD |
| Puurunen J, et al.24 (2013) | 28 PCOS women (atorvastatin group: 40.5 +/- 5.9; placebo group: 38.5 +/- 4.8), randomized double-blind placebo-controlled trial, 6 month follow-up study |
Atorvastatin 20 mg vs. placebo | -TC decreased by 31% vs. 2% -LDL decreased by 45% vs. no change -TG decreased by 25% vs. increased by 9% -No significant change in HDL |
-Fasting insulin levels higher from baseline by 9% at 6 months vs. lower at 1.4% (p = 0.023) -Stimulated AUCs of insulin higher from baseline by 0.2% at 6 months vs. lower by 18% (p = 0.023) -Insulin sensitivity (Matsuda index) decreased by 21% vs. increased by 12% (p = 0.002) -DHEAS decreased 15% (p < 0.001) vs. 10% -Total T did not significantly decrease in atorvastatin group but did in placebo by 22% (p = 0.009) -CRP decreased 23.5% vs. increased by 33% (p < 0.006) |
Androstenedione, T, DHEAS, estradiol, LH, FSH, SHBG, CRP, TC, LDL, HDL TG, glucose |
| Kaya C, et al.25 (2009) | 52 PCOS women (23.4 +/6.2), prospective randomized trial, 12 week study | Atorvastatin 20 mg vs. simvastatin 20 mg daily | -TC decreased by 21% vs. 25% -LDL decreased by 26% vs. 24% -TG not significantly decreased -HDL increased by 21% vs. no significant increase |
-Total T decreased 36.5% (p < 0.01) vs. 46% (p < 0.01) -Free T decreased 38.3% (p = 0.05) vs. 40.6% (p < 0.01) -Homocysteine levels decreased by 26% (p < 0.01) vs. 18% (p < 0.05) -Fasting insulin decreased by 40% (p < 0.01) vs. no significant change |
Serum homocysteine, free and total T levels, FSH, LH, DHEAS, HDL, LDL, TG, total cholesterol |
AUC, area under curve; DHEAS, dehydroepiandrosterone sulfates; hs-CRP, high sensitivity C-reactive protein; FSH, follicle stimulating hormone, FMD, flow mediated dilation; HDL, high density lipoprotein; LDL, low density lipoprotein; M, mean; LH, luteinizing hormone; TC, total cholesterol; TG, triglyceride; T, testosterone.